logo

NGNE

Neurogene·NASDAQ
--
--(--)
--
--(--)
2.69 / 10
Underperform

NGNE's fundamentals are a mixed bag: positive factors include PB-ROE (2/3 score) and Profit-MV (2/3), but negative aspects such as Revenue-MV (1/3) and Gross profit margin (%) (1/3) drag the overall rating to underperform. The low 2.7/10 score signals weak intrinsic strength, and historical back-tests show only modest returns for most metrics, reinforcing a guarded stance. Key red flags are the negative Revenue-MV (-0.2641) and low gross margin (36.7%), which limit upside potential.

Fundamental(2.69)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score1/3
Weight9.42%
1M Return5.63%
Inventory turnover ratio
Value47.88
Score3/3
Weight8.63%
1M Return5.89%
Gross profit margin (%)
Value36.70
Score1/3
Weight0.27%
1M Return0.22%
Profit-MV
Value0.47
Score2/3
Weight13.19%
1M Return7.95%
Net income-Revenue
Value-0.15
Score2/3
Weight13.37%
1M Return8.04%
PB-ROE
Value-0.15
Score2/3
Weight19.27%
1M Return11.23%
Current assets turnover ratio
Value1.78
Score2/3
Weight2.34%
1M Return1.75%
Fixed assets turnover ratio
Value7993.84
Score3/3
Weight1.99%
1M Return1.53%
Asset-MV
Value-0.51
Score1/3
Weight18.47%
1M Return9.84%
Cash-MV
Value-0.07
Score2/3
Weight13.07%
1M Return7.78%
Is NGNE undervalued or overvalued?
  • NGNE scores 2.69/10 on fundamentals and holds a Premium valuation at present. Backed by its -22.79% ROE, 0.00% net margin, -2.89 P/E ratio, 0.93 P/B ratio, and -103.66% earnings growth, these metrics solidify its Underperform investment rating.